Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams Sells 18,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Lewis Williams sold 18,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the transaction, the director owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This trade represents a 69.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $82.99 on Thursday. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54. The company has a market capitalization of $5.19 billion, a P/E ratio of 133.86 and a beta of 2.26. The company’s 50 day simple moving average is $84.80 and its 200 day simple moving average is $75.37.

Institutional Trading of Protagonist Therapeutics

Several institutional investors have recently made changes to their positions in PTGX. KVP Capital Advisors LP purchased a new position in Protagonist Therapeutics during the fourth quarter valued at approximately $4,629,000. Virtus Investment Advisers LLC grew its holdings in shares of Protagonist Therapeutics by 38.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 2,790 shares of the company’s stock valued at $244,000 after acquiring an additional 770 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after acquiring an additional 1,262,977 shares during the last quarter. SummitTX Capital L.P. increased its stake in shares of Protagonist Therapeutics by 34.2% in the fourth quarter. SummitTX Capital L.P. now owns 42,266 shares of the company’s stock worth $3,692,000 after acquiring an additional 10,776 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in shares of Protagonist Therapeutics during the fourth quarter worth $1,895,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on PTGX shares. Citigroup lifted their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Barclays boosted their price objective on Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Jefferies Financial Group upped their price objective on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Citizens Jmp lifted their target price on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Wedbush boosted their price target on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $93.38.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.